HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yorihide Okuda Selected Research

hepatoma-derived growth factor

10/2006Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer.
2/2006Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma.
3/2004Circulating auto-antibody against hepatoma-derived growth factor (HDGF) in patients with ulcerative colitis.
12/2003Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor.
11/2003Expression of hepatoma-derived growth factor in hepatocarcinogenesis.
11/2002Participation of hepatoma-derived growth factor in the regulation of fetal hepatocyte proliferation.
11/2002Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yorihide Okuda Research Topics

Disease

6Neoplasms (Cancer)
11/2012 - 11/2002
5Hepatocellular Carcinoma (Hepatoma)
03/2015 - 11/2002
3Chronic Hepatitis C
05/2007 - 01/2003
2Ulcerative Colitis
10/2020 - 03/2004
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2022
1Adenocarcinoma
08/2021
1Pancreatitis
03/2015
1Liver Diseases (Liver Disease)
03/2015
1Obstructive Jaundice (Cholestatic Jaundice)
11/2012
1Duodenal Neoplasms (Duodenal Cancer)
11/2012
1Gallbladder Neoplasms (Gallbladder Cancer)
11/2012
1Familial duodenal atresia
11/2012
1Pathologic Constriction (Stenosis)
11/2011
1Pancreatic Neoplasms (Pancreatic Cancer)
10/2006
1Proctitis
03/2004
1Colitis
03/2004
1Carcinogenesis
12/2003
1Hepatitis
11/2003
1Fatty Liver
11/2003

Drug/Important Bio-Agent (IBA)

7hepatoma-derived growth factorIBA
10/2006 - 11/2002
3RNA (Ribonucleic Acid)IBA
05/2007 - 01/2003
3Amantadine (Aman)FDA LinkGeneric
05/2007 - 01/2003
3InterferonsIBA
05/2007 - 01/2003
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2021 - 12/2003
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022
1Biomarkers (Surrogate Marker)IBA
08/2021
1Bevacizumab (Avastin)FDA Link
08/2021
1SteroidsIBA
10/2020
1Diclofenac (SR 38)FDA LinkGeneric
03/2015
1Contrast MediaIBA
03/2015
1SonazoidIBA
03/2015
1perfluorobutane (AI 700)IBA
03/2015
1Ribavirin (Virazole)FDA LinkGeneric
05/2007
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2006
1Dihydrotachysterol (AT 10)IBA
03/2004
1ImmunosorbentsIBA
03/2004
1Immunoglobulin G (IgG)IBA
03/2004
1EnzymesIBA
03/2004
1AntibodiesIBA
03/2004
1Neutralizing AntibodiesIBA
12/2003
1Amino AcidsFDA Link
11/2003
1Choline (Choline Chloride)IBA
11/2003
1Antisense OligonucleotidesIBA
11/2002
1Conditioned Culture MediaIBA
11/2002
1Liposomes (Liposome)IBA
11/2002
1Proteins (Proteins, Gene)FDA Link
11/2002

Therapy/Procedure

5Therapeutics
10/2020 - 01/2003
3Drug Therapy (Chemotherapy)
08/2021 - 11/2012
2Stents
11/2012 - 11/2011
1Blood Component Removal (Apheresis)
10/2020
1Retreatment
05/2007